Last Updated: June 18, 2026

Litigation Details for Monument Peak Ventures, LLC v. Arashi Vision Inc. d/b/a Insta360 (E.D. Tex. 2025)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Monument Peak Ventures, LLC v. Arashi Vision Inc. d/b/a Insta360
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: Monument Peak Ventures, LLC v. Arashi Vision Inc. d/b/a Insta360 (E.D. Tex. 2025)

Last updated: June 17, 2026

Executive summary

Monument Peak Ventures, LLC v. Arashi Vision Inc. d/b/a Insta360 (D. Del., No. 2:25-cv-00956) is a newly filed federal patent case. No substantive litigation record (claims chart, asserted patents, accused products, scheduling order, Markman briefing, or party motions) is available in the provided prompt, so a complete and accurate litigation summary cannot be produced.

Litigation timeline and procedural posture for Monument Peak Ventures v. Arashi Vision (Insta360) 2:25-cv-00956

No complete case docket facts provided. Without the filing date, asserted patents, parties’ roles (plaintiff, defendant, counterclaims), or docket events, a reliable timeline cannot be compiled.

What typically appears in the docket for a new patent case like 2:25-cv-00956?

  • Complaint filing and jury demand
  • Service, appearance, and first motions
  • Rule 16 scheduling conference and initial scheduling order
  • Disclosure deadlines (initial infringement contentions and invalidity contentions)
  • Markman claim construction briefing schedule
  • Case management order on claim terms and expert exchange

What procedural signals determine the litigation risk profile?

  • Early claim construction targets that narrow infringement scope
  • Whether the case includes ITC-related leverage or parallel proceedings
  • Whether the defendant moves to dismiss for improper venue or failure to state a claim
  • Whether the parties stipulate to stay pending reexamination or parallel USPTO proceedings

What patents does Monument Peak Ventures assert against Arashi Vision in 2:25-cv-00956?

No asserted-patent data in the provided prompt. A valid “which patents are asserted” summary requires the list of patents-in-suit from the complaint.

Key items needed for patent-level analysis

  • Patent numbers and publication equivalents
  • Priority dates and claimed priority chain
  • Independent claims asserted (method, system, apparatus, or product)
  • Representative claim charts (infringement allegations by limitation)
  • Asserted geographic scope and importation theories (if any)

How does the complaint define infringement for Insta360 products?

No accused-product detail is provided. A limitation-by-limitation infringement analysis is impossible without the complaint’s product mapping.

Infringement mapping elements usually covered

  • Capture hardware and sensor architecture
  • Image processing pipeline and firmware/software logic
  • Stabilization, stitching, calibration, and metadata generation
  • Communication interfaces and data formats
  • Packaging and hardware-software integration

What defenses has Arashi Vision raised in Monument Peak Ventures v. Insta360?

No defense content is provided. Any analysis would risk inventing or overstating positions.

Typical patent-defense clusters in early stages

  • Noninfringement at claim construction stage
  • Invalidity arguments (anticipation, obviousness, indefiniteness)
  • Prosecution history estoppel arguments
  • §112 enablement and written description challenges
  • Standing, ownership, and assignment chain issues

Has there been any Markman order or claim construction ruling?

No claim construction events are provided. A litigation effectiveness assessment depends on the court’s constructions and whether they preserve or collapse key infringement theories.

How claim construction changes outcomes in practice

  • Constructions that narrow a limitation can eliminate infringement for firmware-only or alternative processing paths
  • Constructions that broaden a term can force a factual dispute on product configuration and implementation

Are there Paragraph IV or ANDA-type risks in 2:25-cv-00956?

Not applicable to a typical electronics patent suit, and there is no information in the prompt indicating FDA exclusivity, Orange Book listings, or generic entry pathways. This question cannot be answered correctly without knowing the patent subject matter (biopharma versus consumer electronics) and the litigation’s statutory basis.

What is the current settlement or resolution posture for Monument Peak Ventures v. Arashi Vision?

No settlement terms or docket disposition are provided. Any “settled” or “dismissed” claim would be speculative.

Settlement leverage indicators usually visible on docket

  • Stipulations of dismissal without prejudice
  • Consent judgments
  • Confidential settlement references in later orders
  • Voluntary dismissal after claim construction

Commercial impact analysis: revenue exposure for Insta360 if Monument Peak wins

No asserted patents, damages theory, or accused SKUs are provided. A damages exposure model requires:

  • accused product list and sales volumes
  • relevant time period for damages
  • royalty basis (licenses, comparable agreements) or lost profits evidence
  • whether the claims cover a core camera feature versus a peripheral function

Damages inputs typically used in patent cases

  • Number of units sold per accused model
  • Average selling price and gross margin
  • Apportionment arguments (feature-level vs. whole product)
  • Standard of proof for willfulness and enhanced damages

How strong is Monument Peak’s patent estate in similar cases?

No patent numbers or related litigation history are provided. Strength assessment requires:

  • file histories and claim scope
  • family breadth across jurisdictions
  • prior enforcement actions and adverse rulings

Patent strength indicators used by litigators

  • Surviving independent claims post-PTAB (if any)
  • Claim construction history in prior cases
  • Use of broad “means-plus-function” or well-defined structural limitations
  • Prior art proximity at filing dates

Jurisdiction and venue analysis for 2:25-cv-00956 (D. Del.)

No venue dispute information is provided. A venue/transfer analysis needs:

  • defendant’s venue-related filings
  • court’s rulings on transfer (28 USC §1404/§1631)
  • factual ties asserted for Delaware

Delaware-specific litigation dynamics

  • D. Del. practice on patent cases and scheduling
  • The court’s typical approach to staying cases for PTAB proceedings

Key takeaways

  • The case designation “Monument Peak Ventures, LLC v. Arashi Vision Inc. d/b/a Insta360, 2:25-cv-00956” is identified, but no docket substance is provided.
  • A complete, accurate litigation summary requires docket events, asserted patents, and asserted accused products, none of which are present in the prompt.
  • Any patent-by-patent, claim-by-claim, or stage-by-stage analysis would be non-factual without the complaint and docket orders.

FAQs

  1. What is the filing date and assigned judge for Monument Peak Ventures v. Arashi Vision (2:25-cv-00956)?
  2. Which patents are listed as patents-in-suit in Monument Peak Ventures v. Insta360?
  3. What accused Insta360 products or features are alleged to infringe in 2:25-cv-00956?
  4. Have there been any claim construction (Markman) rulings in the case?
  5. What is the projected schedule for infringement contentions, expert reports, and trial in 2:25-cv-00956?

References

  1. (No sources were provided in the prompt; no citations can be generated.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.